The U.S. Food and Drug Administration’s accelerated approval program is meant to give patients early access to promising drugs. But how often do these drugs actually improve or extend patients’ lives?
In a new study, researchers found that most cancer drugs granted accelerated approval do not demonstrate such benefits within five years.
“Five years after the initial accelerated approval, you should have a definitive answer,” said Dr. Ezekiel Emanuel, a cancer specialist and bioethicist at the University of Pennsylvania who was not involved in the research. “Thousands of people are getting those drugs. That seems a mistake if we don’t know whether they work or not.”
The program was created in 1992 to speed access to HIV drugs. Today, 85% of accelerated approvals go to cancer drugs.
It allows the FDA to grant early approval to drugs that show promising initial results for treating debilitating or fatal diseases. In exchange, drug companies are expected to do rigorous testing and produce better evidence before gaining full approval.
Tagovailoa misses Dolphins' OTA day to attend Saban's charity golf tournament
With 'functional' beverages, brands push drinks that do more than taste good
PICTURED: Best friends who died alongside student while 'doing high
Cedric Mullins shines with his glove and bat as the Orioles down the Twins 7
NFL's accelerator program gives minority coaches optimism that new system works
Rescuers battling forest fire in China's Sichuan
Why the royals are no fans of Buckingham Palace... and what it's really like to live there
Woman, 45, suffers horrific and rare reaction to IBUPROFEN
Turkish Airlines resumes flights to Afghanistan nearly 3 years after the Taliban captured Kabul
GENERAL JACOB NAGEL: Why Israel's failure to strike back at Iran could lead to NUCLEAR WAR
Supreme Court: CFPB funding doesn't violate Constitution
TJ Maxx job applicant really wants to to work at the store